Genetic Approaches to Hypothalamic-Pituitary-Adrenal Axis Regulation

Neuropsychopharmacology

Volumn 41, Issue 1, 2016, Pages 245-260

  Arnett, Melinda G ^a,b   Muglia, Lisa M ^a   Laryea, Gloria ^a,c   Muglia, Louis J ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; NEUROPEPTIDE;

BRAIN REGION; DEPRESSION; DIABETES MELLITUS; ENVIRONMENTAL STRESS; FOREBRAIN; GENE TARGETING; GENETIC PROCEDURES; GENOME; HORMONAL REGULATION; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; NONHUMAN; OSTEOPENIA; PARAVENTRICULAR THALAMIC NUCLEUS; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; BRAIN; GENETICS; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; METABOLISM; PHYSIOLOGY; PROTEIN SYNTHESIS;

ANIMALS; BRAIN; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; PROTEIN BIOSYNTHESIS; RECEPTORS, GLUCOCORTICOID; STRESS DISORDERS, POST-TRAUMATIC; STRESS, PSYCHOLOGICAL;

EID: 84949544500     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.215     Document Type: Review

References (114)

1. Ambroggi F, Turiault M, Milet A, Deroche-Gamonet V, Parnaudeau S, Balado E et al (2009). Stress and addiction: glucocorticoid receptor in dopaminoceptive neurons facilitates cocaine seeking. Nat Neurosci 12: 247-249.
2. Amico JA, Cai HM, Vollmer RR (2008). Corticosterone release in oxytocin gene deletion mice following exposure to psychogenic versus non-psychogenic stress. Neurosci Lett 442: 262-266.
3. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP (2009). Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 94: 2692-2701.
4. Andrioli M, Pecori Giraldi F, Cavagnini F (2006). Isolated corticotrophin deficiency. Pituitary 9: 289-295.
5. Araujo RV, Chang CV, Cescato VA, Fragoso MC, Bronstein MD, Mendonca BB et al (2013). PROP1 overexpression in corticotrophinomas: evidence for the role of PROP1 in the maintenance of cells committed to corticotrophic differentiation. Clinics (Sao Paulo) 68: 887-891.
6. Asteria C, Oliveira JH, Abucham J, Beck-Peccoz P (2000). Central hypocortisolism as part of combined pituitary hormone deficiency due to mutations of PROP-1 gene. Eur J Endocrinol 143: 347-352.
7. Auernhammer CJ, Chesnokova V, Melmed S (1998). Leukemia inhibitory factor modulates interleukin- 1beta-induced activation of the hypothalamo-pituitaryadrenal axis. Endocrinology 139: 2201-2208.
8. Bale TL, Lee KF, Vale WW (2002). The role of corticotropin-releasing factor receptors in stress and anxiety. Integr Comp Biol 42: 552-555.
9. Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T et al (2005). Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123: 493-505.
10. Bamberger CM, Schulte HM, Chrousos GP (1996). Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 17: 245-261.
11. Barik J, Marti F, Morel C, Fernandez SP, Lanteri C, Godeheu G et al (2013). Chronic stress triggers social aversion via glucocorticoid receptor in dopaminoceptive neurons. Science 339: 332-335.
12. Bartolomucci A, Leopardi R (2009). Stress and depression: preclinical research and clinical implications. PLoS One 4: e4265.
13. Berger S, Wolfer DP, Selbach O, Alter H, Erdmann G, Reichardt HM et al (2006). Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc Natl Acad Sci USA 103: 195-200.
14. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B et al (2004). Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36: 1319-1325.
15. Bonfiglio JJ, Inda C, Refojo D, Holsboer F, Arzt E, Silberstein S (2011). The corticotropin-releasing hormone network and the hypothalamic-pituitaryadrenal axis: molecular and cellular mechanisms involved. Neuroendocrinology 94: 12-20.
16. Bousquet C, Zatelli MC, Melmed S (2000). Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immunoneuroendocrine interfacing. J Clin Invest 106: 1417-1425.
17. Boyle MP, Brewer JA, Funatsu M, Wozniak DF, Tsien JZ, Izumi Y et al (2005). Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc Natl Acad Sci USA 102: 473-478.
18. Boyle MP, Kolber BJ, Vogt SK, Wozniak DF, Muglia LJ (2006). Forebrain glucocorticoid receptors modulate anxiety-associated locomotor activation and adrenal responsiveness. J Neurosci 26: 1971-1978.
19. Brewer JA, Khor B, Vogt SK, Muglia LM, Fujiwara H, Haegele KE et al (2003). T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation. Nat Med 9: 1318-1322.
20. Champagne FA, Francis DD, Mar A, Meaney MJ (2003). Variations in maternal care in the rat as a mediating influence for the effects of environment on development. Physiol Behav 79: 359-371.
21. Chesnokova V, Melmed S (2002). Minireview: neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology 143: 1571-1574.
22. Chrousos GP (1995). The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332: 1351-1362.
23. Couture C, Saveanu A, Barlier A, Carel JC, Fassnacht M, Fluck CE et al (2012). Phenotypic homogeneity and genotypic variability in a large series of congenital isolated ACTH-deficiency patients with TPIT gene mutations. J Clin Endocrinol Metab 97: E486-E495.
24. Dale E, Bang-Andersen B, Sanchez C (2015). Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol 95: 81-97.
25. Dalla C, Antoniou K, Drossopoulou G, Xagoraris M, Kokras N, Sfikakis A et al (2005). Chronic mild stress impact: are females more vulnerable? Neuroscience 135: 703-714.
26. Dallman MF, Levin N, Cascio CS, Akana SF, Jacobson L, Kuhn RW (1989). Pharmacological evidence that the inhibition of diurnal adrenocorticotropin secretion by corticosteroids is mediated via type I corticosterone-preferring receptors. Endocrinology 124: 2844-2850.
27. Dallman MF, Strack AM, Akana SF, Bradbury MJ, Hanson ES, Scribner KA et al (1993). Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. Front Neuroendocrinol 14: 303-347.
28. Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS et al (1998). Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 83: 2244-2254.
29. de Kloet ER, Van Acker SA, Sibug RM, Oitzl MS, Meijer OC, Rahmouni K et al (2000). Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int 57: 1329-1336.
30. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M (1998). Brain corticosteroid receptor balance in health and disease. Endocr Rev 19: 269-301.
31. Dempster EL, Burcescu I, Wigg K, Kiss E, Baji I, Gadoros J et al (2007). Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. Arch Gen Psychiatry 64: 1189-1195.
32. Elkabes S, Loh YP, Nieburgs A, Wray S (1989). Prenatal ontogenesis of proopiomelanocortin in the mouse central nervous system and pituitary gland: an in situ hybridization and immunocytochemical study. Brain Res Dev Brain Res 46: 85-95.
33. Fries GR, Vasconcelos-Moreno MP, Gubert C, dos Santos BT, Sartori J, Eisele B et al (2014). Hypothalamic-pituitary-adrenal axis dysfunction and illness progression in bipolar disorder. Int J Neuropsychopharmacol 18.
34. Gathercole LL, Stewart PM (2010). Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol 122: 21-27.
35. Godbout JP, Johnson RW (2006). Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Neurol Clin 24: 521-538.
36. Gomez-Sanchez EP (2011). Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule? Trends Endocrinol Metab 22: 179-187.
37. Hannon R, Croxtall JD, Getting SJ, Roviezzo F, Yona S, Paul-Clark MJ et al (2003). Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. FASEB J 17: 253-255.
38. Harris AP, Holmes MC, de Kloet ER, Chapman KE, Seckl JR (2013). Mineralocorticoid and glucocorticoid receptor balance in control of HPA axis and behaviour. Psychoneuroendocrinology 38: 648-658.
39. Heim C, Newport DJ, Heit S, Graham YP, Wilcox M, Bonsall R et al (2000). Pituitaryadrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 284: 592-597.
40. Herman JP (2013). Neural control of chronic stress adaptation. Front Behav Neurosci 7: 61.
41. Herman JP, McKlveen JM, Solomon MB, Carvalho-Netto E, Myers B (2012). Neural regulation of the stress response: glucocorticoid feedback mechanisms. Braz J Med Biol Res 45: 292-298.
42. Hindelang C, Felix JM, Laurent FM, Klein MJ, Stoeckel ME (1990). Ontogenesis of proopiomelanocortin gene expression and regulation in the rat pituitary intermediate lobe. Mol Cell Endocrinol 70: 225-235.
43. Ivell R, Schmale H, Krisch B, Nahke P, Richter D (1986). Expression of a mutant vasopressin gene: differential polyadenylation and read-through of the mRNA 3′ end in a frame-shift mutant. EMBO J 5: 971-977.
44. Jacobson L, Muglia LJ, Weninger SC, Pacak K, Majzoub JA (2000). CRH deficiency impairs but does not block pituitary-adrenal responses to diverse stressors. Neuroendocrinology 71: 79-87.
45. Jacobson L, Sapolsky R (1991). The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 12: 118-134.
46. Jankord R, Turk JR, Schadt JC, Casati J, Ganjam VK, Price EM et al (2007). Sex difference in link between interleukin-6 and stress. Endocrinology 148: 3758-3764.
47. Keck ME, Kern N, Erhardt A, Unschuld PG, Ising M, Salyakina D et al (2008). Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet 147B: 1196-1204.
48. Keen-Rhinehart E, Michopoulos V, Toufexis DJ, Martin EI, Nair H, Ressler KJ et al (2009). Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol Psychiatry 14: 37-50.
49. Kinlein SA, Wilson CD, Karatsoreos IN (2015). Dysregulated hypothalamic-pituitaryadrenal axis function contributes to altered endocrine and neurobehavioral responses to acute stress. Front Psychiatry 6: 31.
50. Kolber BJ, Boyle MP, Wieczorek L, Kelley CL, Onwuzurike CC, Nettles SA et al (2010). Transient early-life forebrain corticotropin-releasing hormone elevation causes long-lasting anxiogenic and despair-like changes in mice. J Neurosci 30: 2571-2581.
51. Kolber BJ, Roberts MS, Howell MP, Wozniak DF, Sands MS, Muglia LJ (2008). Central amygdala glucocorticoid receptor action promotes fear-associated CRH activation and conditioning. Proc Natl Acad Sci USA 105: 12004-12009.
52. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR et al (1999). Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest 103: 683-689.
53. Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA et al (2002). Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 16: 1638-1651.
54. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A (1998). Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19: 155-157.
55. Kwak SP, Morano MI, Young EA, Watson SJ, Akil H (1993). Diurnal CRH mRNA rhythm in the hypothalamus: decreased expression in the evening is not dependent on endogenous glucocorticoids. Neuroendocrinology 57: 96-105.
56. Lamesch C, Neumann S, Pfaffle R, Kiess W, Paschke R (2002). Adrenocorticotrope deficiency with clinical evidence for late onset in combined pituitary hormone deficiency caused by a homozygous 301-302 delAG mutation of the PROP1 gene. Pituitary 5: 163-168.
57. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A et al (2001). A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104: 849-859.
58. Laryea G, Arnett MG, Muglia LJ (2012). Behavioral studies and genetic alterations in corticotropin-releasing hormone (CRH) neurocircuitry: insights into human psychiatric disorders. Behav Sci (Basel) 2: 135-171.
59. Laryea G, Schutz G, Muglia LJ (2013). Disrupting hypothalamic glucocorticoid receptors causes HPA axis hyperactivity and excess adiposity. Mol Endocrinol 27: 1655-1665.
60. Lee RJ, Hempel J, Tenharmsel A, Liu T, Mathe AA, Klock A (2012). The neuroendocrinology of childhood trauma in personality disorder. Psychoneuroendocrinology 37: 78-86.
61. Leszczynska-Rodziewicz A, Szczepankiewicz A, Dmitrzak-Weglarz M, Skibinska M, Hauser J (2012). Association between functional polymorphism of the AVPR1b gene and polymorphism rs1293651 of the CRHR1 gene and bipolar disorder with psychotic features. J Affect Disord 138: 490-493.
62. Leszczynska-Rodziewicz A, Szczepankiewicz A, Pawlak J, Dmitrzak-Weglarz M, Hauser J (2013). Association, haplotype, and gene-gene interactions of the HPA axis genes with suicidal behaviour in affective disorders. Scientific World Journal 2013: 207361.
63. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB et al (1995). Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 92: 836-840.
64. Maira M, Couture C, Le Martelot G, Pulichino AM, Bilodeau S, Drouin J (2003). The T-box factor Tpit recruits SRC/p160 co-activators and mediates hormone action. J Biol Chem 278: 46523-46532.
65. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S et al (2013). CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31: 833-838.
66. McEwen BS, Stellar E (1993). Stress and the individual. Mechanisms leading to disease. Arch Intern Med. 153: 2093-2101.
67. McKlveen JM, Myers B, Flak JN, Bundzikova J, Solomon MB, Seroogy KB et al (2013). Role of prefrontal cortex glucocorticoid receptors in stress and emotion. Biol Psychiatry 74: 672-679.
68. Morand EF (2000). Corticosteroids in the treatment of rheumatologic diseases. Curr Opin Rheumatol 12: 171-177.
69. Morris JF, Omer S, Davies E, Wang E, John C, Afzal T et al (2006). Lack of annexin 1 results in an increase in corticotroph number in male but not female mice. J Neuroendocrinol 18: 835-846.
70. Muglia L, Jacobson L, Dikkes P, Majzoub JA (1995). Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 373: 427-432.
71. Muglia LJ, Jacobson L, Luedke C, Vogt SK, Schaefer ML, Dikkes P et al (2000). Corticotropin-releasing hormone links pituitary adrenocorticotropin gene expression and release during adrenal insufficiency. J Clin Invest 105: 1269-1277.
72. Muglia LJ, Jacobson L, Weninger SC, Luedke CE, Bae DS, Jeong KH et al (1997). Impaired diurnal adrenal rhythmicity restored by constant infusion of corticotropin-releasing hormone in corticotropin-releasing hormone-deficient mice. J Clin Invest 99: 2923-2929.
73. Nasonkin IO, Ward RD, Bavers DL, Beuschlein F, Mortensen AH, Keegan CE et al (2011). Aged PROP1 deficient dwarf mice maintain ACTH production. PLoS One 6: e28355.
74. Naughton M, Dinan TG, Scott LV (2014). Corticotropin-releasing hormone and the hypothalamic-pituitary-adrenal axis in psychiatric disease. Handb Clin Neurol 124: 69-91.
75. Pace TW, Miller AH (2009). Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann NY Acad Sci 1179: 86-105.
76. Pape HC (2005). GABAergic neurons: gate masters of the amygdala, mastered by dopamine. Neuron 48: 877-879.
77. Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L (2007). Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 104: 83-90.
78. Perretti M, D'Acquisto F (2009). Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9: 62-70.
79. Pryce CR, Ruedi-Bettschen D, Dettling AC, Weston A, Russig H, Ferger B et al (2005). Long-term effects of early-life environmental manipulations in rodents and primates: Potential animal models in depression research. Neurosci Biobehav Rev 29: 649-674.
80. Pulichino AM, Vallette-Kasic S, Tsai JP, Couture C, Gauthier Y, Drouin J (2003). Tpit determines alternate fates during pituitary cell differentiation. Genes Dev 17: 738-747.
81. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF (1994). Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60: 436-444.
82. Raetzman LT, Ross SA, Cook S, Dunwoodie SL, Camper SA, Thomas PQ (2004). Developmental regulation of Notch signaling genes in the embryonic pituitary: Prop1 deficiency affects Notch2 expression. Dev Biol 265: 329-340.
83. Ray DW, Ren SG, Melmed S (1998). Leukemia inhibitory factor regulates proopiomelanocortin transcription. Ann NY Acad Sci 840: 162-173.
84. Regev L, Neufeld-Cohen A, Tsoory M, Kuperman Y, Getselter D, Gil S et al (2011). Prolonged and site-specific over-expression of corticotropin-releasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Mol Psychiatry 16: 714-728.
85. Regev L, Tsoory M, Gil S, Chen A (2012). Site-specific genetic manipulation of amygdala corticotropin-releasing factor reveals its imperative role in mediating behavioral response to challenge. Biol Psychiatry 71: 317-326.
86. Reul JM, de Kloet ER (1985). Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 117: 2505-2511.
87. Reul JM, Gesing A, Droste S, Stec IS, Weber A, Bachmann C et al (2000). The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur J Pharmacol 405: 235-249.
88. Rozeboom AM, Akil H, Seasholtz AF (2007). Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. Proc Natl Acad Sci USA 104: 4688-4693.
89. Schmidt MV, Sterlemann V, Wagner K, Niederleitner B, Ganea K, Liebl C et al (2009). Postnatal glucocorticoid excess due to pituitary glucocorticoid receptor deficiency: differential short- and long-term consequences. Endocrinology 150: 2709-2716.
90. Scott LV, Dinan TG (1998). Vasopressin and the regulation of hypothalamic-pituitaryadrenal axis function: implications for the pathophysiology of depression. Life Sci 62: 1985-1998.
91. Selye H (1936). A syndrome produced by diverse nocuous agents. 1936. Natue 138: 3479.
92. Seney ML, Sibille E (2014). Sex differences in mood disorders: perspectives from humans and rodent models. Biol Sex Differ 5: 17.
93. Shimazaki T, Shingo T, Weiss S (2001). The ciliary neurotrophic factor/leukemia inhibitory factor/gp130 receptor complex operates in the maintenance of mammalian forebrain neural stem cells. J Neurosci 21: 7642-7653.
94. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH et al (1998). Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20: 1093-1102.
95. Solomon MB, Furay AR, Jones K, Packard AE, Packard BA, Wulsin AC et al (2012). Deletion of forebrain glucocorticoid receptors impairs neuroendocrine stress responses and induces depression-like behavior in males but not females. Neuroscience 203: 135-143.
96. Spinedi E, Salas M, Chisari A, Perone M, Carino M, Gaillard RC (1994). Sex differences in the hypothalamo-pituitary-adrenal axis response to inflammatory and neuroendocrine stressors. Evidence for a pituitary defect in the autoimmune disease-susceptible female Lewis rat. Neuroendocrinology 60: 609-617.
97. Steinberg A, Shechter FR, Segal HI (1954). True pituitary Addison's disease, a pituitary unitropic deficiency; fifteen-year follow-up. J Clin Endocrinol Metab 14: 1519-1529.
98. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA et al (2004). The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 113: 302-309.
99. Taylor AD, Cowell AM, Flower J, Buckingham JC (1993). Lipocortin 1 mediates an early inhibitory action of glucocorticoids on the secretion of ACTH by the rat anterior pituitary gland in vitro. Neuroendocrinology 58: 430-439.
100. Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC et al (1999). Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 23: 99-103.
101. Turnbull AV, Smith GW, Lee S, Vale WW, Lee KF, Rivier C (1999). CRF type I receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation. Endocrinology 140: 1013-1017.
102. Tye KM, Deisseroth K (2012). Optogenetic investigation of neural circuits underlying brain disease in animal models. Nat Rev Neurosci 13: 251-266.
103. Uchoa ET, Aguilera G, Herman JP, Fiedler JL, Deak T, de Sousa MBC (2014). Novel aspects of glucocorticoid actions. J Neuroendocrinol 26: 557-572.
104. Vallette-Kasic S, Barlier A, Teinturier C, Diaz A, Manavela M, Berthezene F et al (2001). PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency. J Clin Endocrinol Metab 86: 4529-4535.
105. Vallette-Kasic S, Brue T, Pulichino AM, Gueydan M, Barlier A, David M et al (2005). Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab 90: 1323-1331.
106. van West D, Del-Favero J, Aulchenko Y, Oswald P, Souery D, Forsgren T et al (2004). A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Mol Psychiatry 9: 287-292.
107. Viau V (2002). Functional cross-talk between the hypothalamic-pituitary-gonadal and -adrenal axes. J Neuroendocrinol 14: 506-513.
108. Vincent MY, Jacobson L (2014). Glucocorticoid receptor deletion from the dorsal raphe nucleus of mice reduces dysphoria-like behavior and impairs hypothalamic-pituitary-adrenocortical axis feedback inhibition. Eur J Neurosci 39: 1671-1681.
109. Wang Z, Ren SG, Melmed S (1996). Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuro-endocrine interface. Endocrinology 137: 2947-2953.
110. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR et al (2004). Epigenetic programming by maternal behavior. Nat Neurosci 7: 847-854.
111. Wilson JD (1992). Williams Textbook of Endocrinology. W.B. Saunders: Philadelphia.
112. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U (1999). Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5: 1066-1070.
113. Zelena D, Domokos A, Barna I, Mergl Z, Haller J, Makara GB (2008). Control of the hypothalamo-pituitary-adrenal axis in the neonatal period: adrenocorticotropin and corticosterone stress responses dissociate in vasopressin-deficient brattleboro rats. Endocrinology 149: 2576-2583.
114. Zelena D, Foldes A, Mergl Z, Barna I, Kovacs KJ, Makara GB (2004). Effects of repeated restraint stress on hypothalamo-pituitary-adrenocortical function in vasopressin deficient Brattleboro rats. Brain Res Bull 63: 521-530.